These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38906557)

  • 1. Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study).
    Bauckneht M; Lanfranchi F; Albano D; Triggiani L; Linguanti F; Urso L; Mazzola R; Rizzo A; D'Angelo E; Dondi F; Mataj E; Pedersoli G; Abenavoli EM; Vaggelli L; Detti B; Ortolan N; Malorgio A; Guarneri A; Garrou F; Fiorini M; Grimaldi S; Ghedini P; Iorio GC; Iudicello A; Rovera G; Fornarini G; Bongiovanni D; Marcenaro M; Pazienza FM; Timon G; Salgarello M; Racca M; Bartolomei M; Panareo S; Ricardi U; Bertagna F; Alongi F; Barra S; Morbelli S; Sambuceti G; Belgioia L
    J Nucl Med; 2024 Aug; 65(8):1202-1209. PubMed ID: 38906557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastasis-directed Therapy (SBRT) Guided by PET-CT
    Mazzola R; Francolini G; Triggiani L; Napoli G; Cuccia F; Nicosia L; Livi L; Magrini SM; Salgarello M; Alongi F
    Clin Genitourin Cancer; 2021 Jun; 19(3):230-236. PubMed ID: 32863189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment outcomes of metastasis-directed treatment using
    Hurmuz P; Onal C; Ozyigit G; Igdem S; Atalar B; Sayan H; Akgun Z; Kurt M; Ozkok HB; Selek U; Oymak E; Tilki B; Guler OC; Mustafayev TZ; Saricanbaz I; Rzazade R; Akyol F
    Strahlenther Onkol; 2020 Nov; 196(11):1034-1043. PubMed ID: 32617620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.
    De Bruycker A; Spiessens A; Dirix P; Koutsouvelis N; Semac I; Liefhooghe N; Gomez-Iturriaga A; Everaerts W; Otte F; Papachristofilou A; Scorsetti M; Shelan M; Siva S; Ameye F; Guckenberger M; Heikkilä R; Putora PM; Zapatero A; Conde-Moreno A; Couñago F; Vanhoutte F; Goetghebeur E; Reynders D; Zilli T; Ost P
    BMC Cancer; 2020 May; 20(1):406. PubMed ID: 32398040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligometastatic Prostate Cancer Treated with Metastasis-Directed Therapy Guided by Positron Emission Tomography: Does the Tracer Matter?
    Lanfranchi F; Belgioia L; Marcenaro M; Zanardi E; Timon G; Riondato M; Giasotto V; Zawaideh JP; Tomasello L; Mantica G; Piol N; Borghesi M; Traverso P; Satragno C; Panarello D; Scaffidi C; Romagnoli A; Rebuzzi SE; Coco A; Spina B; Morbelli S; Sambuceti G; Terrone C; Barra S; Fornarini G; Bauckneht M
    Cancers (Basel); 2023 Jan; 15(1):. PubMed ID: 36612319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment.
    Bianchi L; Ceci F; Balestrazzi E; Costa F; Droghetti M; Piazza P; Pissavini A; Presutti M; Farolfi A; Mei R; Castellucci P; Gandaglia G; Larcher A; Robesti D; Mottrie A; Briganti A; Morganti AG; Fanti S; Montorsi F; Schiavina R; Brunocilla E
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis.
    Glicksman RM; Metser U; Vines D; Valliant J; Liu Z; Chung PW; Bristow RG; Finelli A; Hamilton R; Fleshner NE; Perlis N; Zlotta AR; Green D; Bayley A; Helou J; Raman S; Kulkarni G; Catton C; Lam T; Chan R; Warde P; Gospodarowicz M; Jaffray DA; Berlin A
    Eur Urol; 2021 Sep; 80(3):374-382. PubMed ID: 33685838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of PSMA PET-derived Parameters and Outcomes of Patients Treated for Oligorecurrent Prostate Cancer.
    Murad V; Glicksman RM; Berlin A; Santiago A; Ramotar M; Metser U
    Radiology; 2023 Dec; 309(3):e231407. PubMed ID: 38051188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.
    Steuber T; Jilg C; Tennstedt P; De Bruycker A; Tilki D; Decaestecker K; Zilli T; Jereczek-Fossa BA; Wetterauer U; Grosu AL; Schultze-Seemann W; Heinzer H; Graefen M; Morlacco A; Karnes RJ; Ost P
    Eur Urol Focus; 2019 Nov; 5(6):1007-1013. PubMed ID: 29530632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.
    Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Christiansen H; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M
    Eur Urol Focus; 2021 Mar; 7(2):309-316. PubMed ID: 31495759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [
    Vogel MME; Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Mix M; la Fougère C; Eiber M; Christiansen H; Belka C; Grosu AL; Müller AC; Guckenberger M; Combs SE
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2328-2338. PubMed ID: 32179961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
    Ost P; Reynders D; Decaestecker K; Fonteyne V; Lumen N; De Bruycker A; Lambert B; Delrue L; Bultijnck R; Claeys T; Goetghebeur E; Villeirs G; De Man K; Ameye F; Billiet I; Joniau S; Vanhaverbeke F; De Meerleer G
    J Clin Oncol; 2018 Feb; 36(5):446-453. PubMed ID: 29240541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?
    Rans K; Charlien B; Filip A; Olivier H; Julie DH; Céderic D; Herlinde D; Benedikt E; Karolien G; Annouschka L; Nick L; Kenneth P; Carl S; Koen S; Hans V; Ben V; Steven J; Gert M
    BMC Cancer; 2022 Dec; 22(1):1294. PubMed ID: 36503429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer.
    Nikitas J; Castellanos Rieger A; Farolfi A; Seyedroudbari A; Kishan AU; Nickols NG; Steinberg ML; Valle LF; Rettig M; Czernin J; Calais J
    J Nucl Med; 2024 Sep; 65(9):1387-1394. PubMed ID: 39089811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage extended field or involved field nodal irradiation in
    Lépinoy A; Silva YE; Martin E; Bertaut A; Quivrin M; Aubignac L; Cochet A; Créhange G
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):40-48. PubMed ID: 30267117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Hormone-Sensitive Oligorecurrent Prostate Cancer Patients Based on Routine Use of Choline and/or PSMA PET/CT to Guide Metastasis-Directed Therapy.
    Metz R; Rauscher A; Vaugier L; Supiot S; Drouet F; Campion L; Rousseau C
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligometastatic Bone Disease in Castration-Sensitive Prostate Cancer Patients Treated With Stereotactic Body Radiotherapy Using 68Ga-PSMA PET/CT: TROD 09-004 Study.
    Onal C; Ozyigit G; Akgun Z; Atalar B; Igdem S; Oymak E; Agaoglu F; Selek U; Guler OC; Hurmuz P; Mustafayev TZ; Akyol F
    Clin Nucl Med; 2021 Jun; 46(6):465-470. PubMed ID: 33661210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy.
    Milenkovic U; Kuijk J; Roussel E; Devos G; Van den Broeck T; Van Eecke H; Vanderstichele A; Duvillier T; Verhamme L; Van Haute W; Goeman L; Berghen C; Joniau S; De Meerleer G
    Eur Urol Oncol; 2023 Dec; 6(6):582-589. PubMed ID: 36878753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.